Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
NCT00806286
Completed
The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. The study will find out if adding CS-7017 to carboplatin and paclitaxel will be s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2020
Locations: University Colorado Cancer Center, Aurora, Colorado +27 locations
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer
NCT03344172
Terminated
This is a randomized phase II trial that will examine the ability of Avelumab to improve the clinical activity of a pre-operative regimen of gemcitabine, nab-paclitaxel and hydroxychloroquine in subjects with potentially resectable adenocarcinoma of the pancreas.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/30/2020
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Pancreatic Cancer Resectable
Register for Updates
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
NCT01133678
Terminated
Primary Compare response rates (relative change in tumor size) to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab +/- everolimus. Secondary: Determine the maximum administered dose (MAD), maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety of everolimus with cisplatin/paclitaxel/cetuximab induction chemotherapy (phase I portion)
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/29/2020
Locations: The University of Chicago Medical Center, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Breast Cancer
NCT00003088
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at different times or combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy consisting of either doxorubicin, cyclophosphamide, or paclitaxel given at different times with that of combination chemoth... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2020
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +18 locations
Conditions: Breast Cancer
Register for Updates
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
NCT01711970
Completed
This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum resistant ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/23/2020
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Platinum Resistant Ovarian Cancer
Register for Updates
PD0332991/Paclitaxel in Advanced Breast Cancer
NCT01320592
Completed
This study is a phase I, single arm, open-label trial of PD0332991 in combination with Paclitaxel in patients with Rb-expressing metastatic breast cancer. Up to 20 patients are anticipated to be enrolled to reach the Maximum Tolerated Dose (MTD) of PD0332991 in combination with Paclitaxel. Once the MTD is established, an additional expanded cohort of 10 patients will be enrolled at that dose to establish the Recommended Phase 2 Dose (RP2D), obtain additional safety data and perform exploratory b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2020
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
NCT00472693
Completed
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/06/2020
Locations: Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
NCT02265510
Terminated
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2020
Locations: Not set, Birmingham, Alabama +13 locations
Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
Register for Updates
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
NCT02366949
Completed
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2020
Locations: Not set, Santa Monica, California +6 locations
Conditions: Medical Oncology
Register for Updates
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
NCT00006229
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/02/2020
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +68 locations
Conditions: Lung Cancer
Register for Updates
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
NCT01831089
Completed
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2020
Locations: Not set, New York, New York +2 locations
Conditions: Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
Register for Updates
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
NCT01855828
Completed
The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin) concomitant with paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide (T-FEC). The study will also test the safety of this therapy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/18/2020
Locations: Yale University Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Her2-Positive Breast Cancer
Register for Updates